Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Clinical Kidney JournalOpen Access

Extended-Release Calcifediol Identifies a Therapeutic Vitamin D Range in Chronic Kidney Disease stage 3-4

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJohn ChoeAAAkhtar AshfaqCBCharles W. Bishop

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates vitamin D levels reducing parathyroid hormone in chronic kidney disease, indicating an effective treatment range.

Key Points

  • This research aims to define adequate serum vitamin D levels for managing parathyroid hormone in chronic kidney disease.
  • Evaluated exposure-response relationships using pooled data from randomized trials of extended-release calcifediol.
  • Characterized changes in parathyroid hormone (iPTH) as a function of serum 25-hydroxyvitamin D (25D) levels.
  • Assessed associations between achieved 25D and mineral metabolism markers.
  • A population-average serum 25D of 84 ng/mL is linked to a 30% reduction in iPTH, with a range of 67–103 ng/mL across kidney function.
  • No adverse changes in calcium, phosphorus, or fibroblast growth factor-23 were associated with higher achieved 25D levels.
  • Baseline body weight and sex significantly influenced achieved 25D concentrations.

Cite This Study

Choe et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf4dafaef96ed7f057135https://doi.org/10.1093/ckj/sfag194
View Full Paper
Ask AI
Bookmark
Share